Learn more about Peter Attia’s digital program
#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
#255 ‒ Latest therapeutics in CVD, APOE’s role in Alzheimer’s disease and CVD, familial hypercholesterolemia, and more | John Kastelein, M.D., Ph.D.
“One of the things that is so dangerous about this disorder is that the plaque that you get in FH is a soft plaque.” —John Kastelein
#240 ‒ The confusion around HDL and its link to cardiovascular disease | Dan Rader, M.D.
“HDL cholesterol itself is not directly and causally protective against atherosclerotic cardiovascular disease.” —Dan Rader
#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease
“ApoB is a necessary, though not sufficient, factor in the development of ASCVD which means the more you lower it, the more you lower risk. Full stop.” —Peter Attia
#229 ‒ Understanding cardiovascular disease risk, cholesterol, and apoB
“Not everybody dies from atherosclerosis, but… everybody dies with it.” —Peter Attia
Heart Disease: Labs & Diagnostic Tests
This video clip is from episode #203 — AMA #34: What causes heart disease? — originally released on April 18,…
Lp(a) and CVD risk & clinical tests to measure Lp(a)
This video clip is from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D., originally…
Peter’s approach to managing patients with high Lp(a)
This video is a clip from episode #210 – Lp(a) and its impact on heart disease with Benoît Arsenault, Ph.D.,…
#210 – Lp(a) and its impact on heart disease | Benoît Arsenault, Ph.D.
“I think we should advise people to measure Lp(a); that would be a gigantic step.” —Benoît Arsenault
#203 – AMA #34: What Causes Heart Disease?
“Not everybody dies from atherosclerosis, but… everybody dies with it.” — Peter Attia